

Based on the attached "Stock Detailed Analysis Report" for **AUROPHARMA.NS**, here is my assessment as a Positional Equity Trader.

Step 1: Audit the Data

Data Present:

- Price Structure:** Daily and Weekly candlestick charts.
 - Trend Indicators:** EMA 20, 50, 200; Supertrend; MACD.
 - Momentum/Oscillators:** RSI (14), Relative Strength (RS) against Benchmark.
 - Volatility:** Bollinger Bands (width and %B), Volatility Squeeze indicators.
 - Volume:** Volume moving averages, accumulation/distribution signals.
 - Fundamentals:** Snapshot of Revenue/Net Income growth (4-year and 6-quarter).
- #### **Data Missing:**
- Derivatives Data:** Open Interest (OI) build-up or PCR (Put-Call Ratio) to gauge sentiment.
 - Sector Breadth:** While RS against CNXPHARMA is shown, broader sector breadth (how many other pharma stocks are participating) is limited.
- Confidence Level:** **High.** The technical report is comprehensive, covering trend, momentum, volatility, and volume analysis sufficient for a positional trade decision.

Step 2: Analyze the Setup

1. Trend & Structure:

- Conflict of Timeframes:** The stock is in a **Weekly Uptrend** but a **Daily Downtrend**.
- Critical Support Test:** The current price (**1172.70**) is sitting precariously just above the **200-day EMA (1161.45)**. This is the "line in the sand" for the long-term trend.
- Short-Term Weakness:** The price is trading below both the 20 EMA (1195) and 50 EMA (1186). The Supertrend flipped to **SELL** on Jan 13, 2026.

2. Momentum & Volatility:

- Volatility Squeeze:** A "Volatility Squeeze" is active (BB Width 0.067). This indicates potential energy storage for a significant move. Typically, trading below the midline (20 SMA) during a squeeze favors a downside breakout, *but* the proximity to the 200 EMA support complicates this.
- Bearish Momentum:** MACD is negative, and the histogram shows strengthening downside momentum. RSI is at 42.91, which is bearish but not yet oversold.
- Fundamental Headwinds:** Short-term fundamentals are deteriorating (Recent QoQ Revenue -7.03%, Net Income -8.71%), which validates the recent price drop.

3. Confluence:

- Bullish Case:** Price is at 200 EMA support + Volume Analysis shows "Selling Exhaustion (**Bullish** Div)" on Jan 13.
- Bearish Case:** Price below 20/50 EMAs + Supertrend Sell + Weak quarterly results.

Conclusion: The setup is currently a **"Falling Knife."** While the stock is at a major value zone (200 EMA), momentum is decisively down. Entering now is high-risk as the squeeze could fire downwards, breaking the 200 EMA.

Step 3: Formulate the Recommendation

****Recommendation: NO****

Do not enter at the current market price. The momentum is negative, and the stock needs to prove it can hold the 200 EMA and reclaim short-term averages before a long position is justified.

****Conditional Plan (Watchlist for Reversal):****

We are looking for a "Mean Reversion" setup where the stock bounces off the 200 EMA and the Volatility Squeeze fires upward.

* ****Condition to Buy:**** The stock must close ****above the daily 20 EMA**** (currently ~1195). This confirms that the 200 EMA support held and the short-term trend has shifted back to neutral/bullish.

* ****Entry Price:**** ****INR 1,200 - INR 1,205**** (Limit order upon confirmation of a close above 20 EMA).

* ****Stop Loss:**** ****INR 1,150**** (Hard stop below the 200 EMA and recent swing lows).

* ***Risk:*** ~4.0%

* ****Take Profit:**** ****INR 1,350**** (Targeting the recent resistance cluster and upper Bollinger Band).

* ***Reward:*** ~12.5%

* ***Risk/Reward Ratio:*** 1:3 (Favorable).

News & Analyst Targets

Here is the latest news and analysis for ****Aurobindo Pharma (AUROPHARMA)**** for the week of January 17, 2026.

1) Latest News for AUROPHARMA This Week

* ****USFDA Observations for Unit-IV:**** The company's subsidiary, ****APL Healthcare****, received a ****Form 483 with 5 observations**** from the USFDA for its Unit-IV facility in Andhra Pradesh following an inspection that concluded in mid-December. The company has clarified that these observations are ****procedural in nature**** and are not expected to impact operations or financials. A separate unit (Apitoria Pharma) also recently received 3 procedural observations.

* ****Competitor Approval & Acquisition Impact:**** A competitor, ****Respirent Pharmaceuticals (partnered with Lannett)****, received USFDA approval for a generic version of ****Advair Diskus**** (asthma inhaler). This is significant because Aurobindo is in the process of acquiring ****Lannett Company**** (a deal valued at ~\$250 million announced in July 2025). This approval could potentially strengthen Aurobindo's future respiratory portfolio once the acquisition closes, which is expected within the next two months.

* ****Completion of Khandelwal Labs Acquisition:**** On ****January 1, 2026****, Aurobindo Pharma's subsidiary successfully completed the acquisition of the ****non-oncology formulation business of Khandelwal Laboratories**** for approximately ****INR 325 Crore****. This all-cash deal adds brands in the pain management and anti-infective segments to its domestic portfolio.

* ****Trading Window Closure:**** The trading window for the company's shares has been closed effective ****January 1, 2026****, for all designated persons ahead of the declaration of the Q3 FY26 financial results.

2) Upgrade/Downgrade from Brokerages

* ****CLSA Upgrade:**** Global brokerage ****CLSA**** has reportedly upgraded Aurobindo Pharma from ****"Hold" to "Outperform"***** in a recent January 2026 note.

* ****Reasoning:**** The upgrade follows a recent correction in the stock price (down ~11-20% from highs), which CLSA sees as a buying opportunity.

* ****Caveat:**** Despite the rating upgrade, CLSA ****cut its target price to INR 1,400**** (down from INR 1,540) to reflect updated earnings multiples and a conservative outlook for FY27.

* ****Domestic Sentiment:**** Most domestic brokerages (like ****Motilal Oswal**** and ****ICICI Securities****) have maintained a ****"Buy"***** or positive stance, citing the company's valuation comfort relative to peers and the steady integration of recent acquisitions, despite the regulatory observations.

* ****MarketsMojo:**** Currently has a ****"Hold"***** rating on the stock as of early January 2026, citing flat financial trends but attractive valuation.

3) Other News Impacting AUROPHARMA

- * **Pharma Sector Rally:** The broader Nifty Pharma index has seen a mild rally this week, driven by positive notes from brokerages like **HDFC Securities** regarding the growth of the Indian CDMO (Contract Development and Manufacturing) market. This sector-wide optimism is indirectly supporting Aurobindo's stock price.
- * **US Generic Market Dynamics:** The approval of multiple generic Advair competitors signals intensifying competition in the complex generics space in the US. While this pressures pricing, Aurobindo's diversified portfolio and upcoming Lannett acquisition are seen as strategic hedges against this erosion.

**4) Latest Analyst Targets

Below is a summary of the latest price targets and recommendations from the analyst community for January 2026.

Brokerage / Firm	Rating	Target Price (INR)	Sentiment
---	---	---	---
Motilal Oswal		BUY	1,430
			Bullish
CLSA	OUTPERFORM	1,400	Bullish (Upgraded)
ICICI Direct		1,375	Bullish
Trendlyne Consensus		1,349	Moderate Buy
Axis Direct		1,345	Bullish
MarketsMojo	HOLD	N/A	Neutral

Note: Target prices are subject to change based on daily market movements and new report issuances.


Stock Detailed Analysis Report

AUROPHARMA.NS

Current Price: ₹1172.70

Generated: 2026-01-17 18:02

AUROPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

AUROPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	51.8/100
:	

== RS RATIOS ==:

1M RS:	1.018 [Leader]
3M RS:	1.052 [Leader]
6M RS:	1.030 [Leader]
1Y RS:	1.050 [Leader]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✗ Emerging RS:	Not accelerating
✗ Medium-term Lagging:	Not lagging
✓ Performance Improving:	3M (+5.7%) > 6M (+2.2%)

Relative Strength Analysis: AUROPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1195.07
EMA 50:	1186.24
EMA 200:	1161.45
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-25 00:00:00+05:30
Golden Cross Price:	1208.00


AUROPHARMA.NS EMA Crossover Analysis



AUROPHARMA.NS - Bollinger Bands Summary

Current Price:	1172.70
Upper Band:	1242.54
Middle Band (SMA 20):	1202.23
Lower Band:	1161.92
%B:	0.1337
Band Width:	0.0671
Status:	Lower Half
Signal:	None


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



AUROPHARMA.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	1242.99
Signal Identified On:	2026-01-13


Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




AUROPHARMA.NS - MACD Summary

MACD Line:	-3.82
Signal Line:	1.28
Histogram:	-5.10
Trend:	Bearish
Momentum:	Strengthening
Signal:	None

AUROPHARMA.NS Price






AUROPHARMA.NS MACD (12, 26, 9)



AUROPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.0671
ATR:	28.5214
Total Signals:	40
Signal 1:	BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 1206.10)
Signal 2:	BB Squeeze at 2026-01-09 00:00:00+05:30 (Price: 1198.70)
Signal 3:	BB Squeeze at 2026-01-12 00:00:00+05:30 (Price: 1172.90)
Signal 4:	BB Squeeze at 2026-01-13 00:00:00+05:30 (Price: 1167.70)
Signal 5:	BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1180.10)

AUROPHARMA.NS - Volatility Squeeze Analysis



AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	42.91
Current Volume:	909022
Volume MA 20:	905264
Bullish Divergences:	1
Bearish Divergences:	2
Bullish Div 1:	Date: 2025-02-03 00:00:00+05:30, Price: 1121.19
Bearish Div 1:	Date: 2024-08-30 00:00:00+05:30, Price: 1563.53
Bearish Div 2:	Date: 2025-10-13 00:00:00+05:30, Price: 1136.80

AUROPHARMA.NS RSI-Volume Divergence Analysis



AUROPHARMA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

121 Signals Detected

:

2025-12-31 [-]:

Distribution Day

2026-01-07 [-]:

Climax Volume (Churning)

2026-01-09 [-]:

Distribution Day

2026-01-13 [+]:

Selling Exhaustion (Bullish Div)

2026-01-16 [-]:

Distribution Day

AUROPHARMA.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1122.17	1172.7	2025-11-10
1 Day	DOWNTREND (Sell)	1242.99	1172.7	2026-01-13
15 Min	DOWNTREND (Sell)	1180.9	1172.7	2026-01-16

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Strengthening	No Signal
15 Min	Bearish	Weakening	No Signal

AUROPHARMA.NS - 1 Week (Candlestick + EMAs)




AUROPHARMA.NS - 1 Day (Candlestick + EMAs)



AUROPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - AUROPHARMA_main



Trendlyne Snapshot - AUROPHARMA_forecaster

MarketsSTARFOLIOAlertsF&OMFReportsScreenersSubscribeSuperstarsPortfolioWatchlistInsider TradesResultsData DownloaderMore

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

In 5 Starfolio Baskets

1172.70-7.40 (-0.63%)

922.4K NSE+BSE Volume
NSE 16 Jan, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

Aurobindo Pharma - AUROPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 28 analysts

Aurobindo Pharma has a share price target of Rs 1307, revenue growth forecast of 4.8%, and profit growth estimate of 4.4% for FY26, based on top 28 analyst calls.

Aurobindo Pharma FORECASTER - Analyst Estimates

[FORECASTER DASHBOARD](#)

SHARE PRICE TARGET FORECAST12 MONTH ESTIMATE

The chart displays the share price target forecast for Aurobindo Pharma. The current price is 1172.7. The average estimate is 1306.6. The 12-month target is 1307. The low estimate is 730 and the high estimate is 1640.

Category	Value
Current Price	1172.7
Avg. Estimate	1306.6
Low Estimate	730
High Estimate	1640

HIT Aurobindo Pharma's share price target is above the current price, with an upside of 11.4%

EPS FORECASTQUARTERANNUAL

The chart displays the EPS forecast for Aurobindo Pharma. The actual EPS is shown as a blue line with diamond markers, and the average estimate is shown as a red line with circle markers. The forecast is for the next 3 years, from Mar '23 to Mar '27.

Year	Actual EPS	Avg. Estimate
Mar '23	35	35
Mar '24	55	55
Mar '25	65	65
Mar '26	65	65
Mar '27	75	75

MISS Aurobindo Pharma's EPS was lower than average estimate 2 times in past 3 years

CONSENSUS RECOMMENDATION28 ANALYST Recommendations

The chart displays the consensus recommendation from 28 analysts for Aurobindo Pharma. The consensus recommendation is BUY. The chart shows the number of analysts recommending each rating over time.

Rating	Count	Percentage	Time Period
Strong Buy	18	5	Aug '25
Buy	5	2	Sep '25
Sell	1	3	Oct '25
Strong Sell	4	3	Nov '25
Strong Buy	18	5	Dec '25
Buy	5	2	Jan '26
Sell	1	3	
Strong Sell	4	3	

BUY The consensus recommendation from 28 analysts for Aurobindo Pharma is BUY